A time-resolved fluorescence-resonance energy transfer assay for identifying inhibitors of hepatitis c virus core dimerization

Assay and Drug Development Technologies

Volumn 8, Issue 1, 2010, Pages 96-105

  Kota, Smitha ^a   Scampavia, Louis ^a   Spicer, Timothy ^a   Beeler, Aaron B ^b   Takahashi, Virginia ^a   Snyder, John K ^b   Porco, John A ^b   Hodder, Peter ^a   Strosberg, Arthur Donny ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b BOSTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPHYCOCYANIN; ANTIBODY; CORE PROTEIN; EUROPIUM; GLUTATHIONE TRANSFERASE;

AMINO TERMINAL SEQUENCE; ANTIBODY LABELING; ARTICLE; BIOASSAY; CELL CULTURE; CONTROLLED STUDY; DIMERIZATION; DOSE RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE RESONANCE ENERGY TRANSFER; HEPATITIS C VIRUS; HEPATOMA CELL; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IC 50; NONHUMAN; PROTEIN PROTEIN INTERACTION; TIME; VIRUS CORE;

ANTIVIRAL AGENTS; DRUG EVALUATION, PRECLINICAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE RESONANCE ENERGY TRANSFER; HEPACIVIRUS; PROTEIN MULTIMERIZATION; VIRAL CORE PROTEINS;

EID: 77649154253     PISSN: 1540658X     EISSN: None     Source Type: Journal    
DOI: 10.1089/adt.2009.0217     Document Type: Article

References (24)

1. WHO: Hepatitis C: global prevalence. Wkly Epidemiol Rec 1997; 72:341-344.
2. Giannini C, Brechot C: Hepatitis C virus biology. Cell Death Differ 2003;10(Suppl. 1):S27-S38.
3. Choo Q, Kuo G, Weiner A, Overby L, Bradley D, Houghton M: Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989;244(4902):359.
4. McGovern BH: Hepatitis C in the HIV-infected patient. J Acquir Immune Defic Syndr 2007;45(Suppl 2):S47-S56.
5. Cristina J, Moreno-del Pilar M, Moratorio G: Hepatitis C virus genetic variability in patients undergoing antiviral therapy. Virus Res 2007;127(2):185-194. (Pubitemid 47058198)
6. De Francesco R, CarfiA: Advances in the development of new therapeutic agents targeting the NS3-4A serine protease or the NS5B RNA-dependent RNA polymerase of the hepatitis C virus. Adv Drug Del Revs 2007;59(12): 1242-1262.
7. Thibeault D, Bousquet C, Gingras R, Lagace L, Maurice R, White PW, et al.: Sensitivity of NS3 serine proteases from hepatitis C virus genotypes 2 and 3 to the inhibitor BILN 2061. J Virol 2004;78(14):7352-7359.
8. Courcambeck J, Bouzidi M, Perbost R, Jouirou B, Amrani N, Cacoub P, et al.: Resistance of hepatitis C virus to NS3-4A protease inhibitors: mechanisms of drug resistance induced by R155Q, A156T, D168A and D168V mutations. Antivir Ther 2006;11(7):847-855.
9. McLauchlan J: Properties of the hepatitis C virus core protein: a structural protein that modulates cellular processes. J Viral Hepat 2000;7:2-14.
10. Kota S, Coito C, Mousseau G, Lavergne J-P, Strosberg AD: Peptide inhibitors of Hepatitis C Virus core oligomerization and virus production. J Gen Virol 2009;90:1319-1328.
11. Beeler AB, Acquilano DE, Su Q, Yan F, Roth BL, Panek JS, et al.: Synthesis of a library of complex macrodiolides employing cyclodimerization of hydroxy esters. J Comb Chem 2005;7:673-681.
12. Lei X, Zaarur N, Sherman MY, Porco JA, Jr.: Stereocontrolled synthesis of a complex library via elaboration of angular epoxyquinol scaffolds. J Org Chem 2005;70:6474-6483.
13. Zhou Y, Beeler AB, Cho S, Wang Y, Franzblau SG, Snyder JK: Library synthesis using 5,6,7,8-Tetrahydro-1,6-naphthyridines as Scaffolds. J Comb Chem 2008;10:534-540.
14. Su S, Acquilano DE, Arumugasamy J, Beeler AB, Eastwood EL, Giguere JR, et al.: Convergent synthesis of a complex oxime library using chemical domain Shuffling. Org Lett 2005;7:2751-2754.
15. Preaudat M, Ouled-Diaf J, Alpha-Bazin B, Mathis G, Mitsugi T, Aono Y, et al.: A homogeneous caspase-3 activity assay using HTRF technology. J Biomol Screen 2002;7(3):267-274.
16. Mathias G: HTRF technology. J Biomol Screen 1999;4:309-313.
17. Peppard J, Glickman F, He Y, Hu SI, Doughty J, Goldberg R: Development of a high-throughput screening assay for inhibitors of aggrecan cleavage using luminescent oxygen channeling (ALPHA screen). J Biomol Screen 2003;8(2):149-156.
18. Lindenbach BD, Evans MJ, Syder AJ, Wolk, B, Tellinghuisen TL, Liu CC, et al.: Complete replication of hepatitis C virus in cell culture. Science 2005;309: 623-626.
19. Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z, et al.: Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 2005;11:791-796.
20. Zhong J, Gastaminza P, Cheng G, Kapadia S, Kato T, Burton DR, et al.: Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci USA 2005;102:9294-9299.
21. Tellinghuisen TL, Foss KL, Treadaway J: Regulation of Hepatitis C virion production via phosphorylation of the NS5A protein. PLoS Pathog 2008;4(3):e1000032.
22. Jones CT, Murray CL, Eastman DK, Tassello J, Rice CM: Hepatitis C virus p7 and NS2 proteins are essential for production of infectious virus. J Virol 2007;81:8374-8383.
23. Wells JA, McClendon CL: Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature 2007;450:1001-1009.
24. Stray SJ, Johnson JM, Kopek BG, Zlotnick A: An in vitro fluorescence screen to identify antivirals that disrupt hepatitis B virus capsid assembly. Nat Biotechnol 2007;24:358-362.